Showing 901 - 920 results of 9,652 for search 'significantly ((((less decrease) OR (larger decrease))) OR (((we decrease) OR (mean decrease))))', query time: 0.59s Refine Results
  1. 901
  2. 902
  3. 903

    Contains R code utilized in the analyses. by Arttu Autio-Kimura (20454681)

    Published 2024
    “…Spearman correlation analysis between the individuals’ calendar ages and cell type proportions revealed a statistically significant decrease in the proportion of neurons with increasing age. …”
  4. 904
  5. 905
  6. 906
  7. 907
  8. 908
  9. 909
  10. 910
  11. 911

    Flow chart of experimental protocol. by Eun-Seon Yang (19751340)

    Published 2024
    “…SBP showed an increasing trend, but this was not statistically significant (<i>p</i> = 0.108). Interestingly, we observed significant decreases in arterial stiffness and PWV in POST_VM when comparing with PRE_VM (<i>p</i><0.001 and <i>p</i><0.001, respectively). …”
  12. 912

    A representative ultrasound axis image. by Eun-Seon Yang (19751340)

    Published 2024
    “…SBP showed an increasing trend, but this was not statistically significant (<i>p</i> = 0.108). Interestingly, we observed significant decreases in arterial stiffness and PWV in POST_VM when comparing with PRE_VM (<i>p</i><0.001 and <i>p</i><0.001, respectively). …”
  13. 913
  14. 914
  15. 915
  16. 916
  17. 917
  18. 918
  19. 919

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  20. 920

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”